Clinical trials: Non-proliferative Diabetic Retinopathy
Non-Proliferative Diabetic Retinopathy
To Evaluate the Efficacy and Safety of Combination Therapy With B55R1 and B55R2 Compared to B55R1 Monotherapy in Patients With NPDR
This study is planned to evaluate the efficacy and safety of combination therapy with B55R1 and B55R2 compared to B55R1 monotherapy in patients with non-proliferative diabetic retinopathy (NPDR).
- Trial name
- NCT07230184
- Testing
- B55R1 and B55R2
- Where
- South Korea
- Volunteers
- 53 people
- Sponsor
- AJU Pharm Co., Ltd.
Proliferative Diabetic Retinopathy
Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy
The RECOVERY trial will assess the safety and tolerability of 2 mg intravitreal aflibercept injections (IAI) given monthly (Q4WK) or every 12 weeks (Q12WK) for the treatment of retinal capillary non-perfusion (RNP) associated…
- Trial name
- RECOVERY (NCT02863354)
- Testing
- Aflibercept
- Where
- 4 sites in United States
- Volunteers
- 43 people
- Sponsor
- Charles C Wykoff, PhD, MD
Diabetes Mellitus - Type 1, Diabetes Mellitus - Type 2
Diabetes Visual Function Supplement Study
This study will evaluate the effects of a novel multi-component dietary supplement on the visual function and retinal structure of patients with diabetes with both no diabetic retinopathy and mild to moderate diabetic…
- Conditions
- Diabetes Mellitus - Type 1, Diabetes Mellitus - Type 2, Non-proliferative Diabetic Retinopathy
- Trial name
- DiVFuSS (NCT01646047)
- Testing
- multi-component nutritional supplement capsules, multi-component dietary supplement
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- ZeaVision, LLC
Diabetic Retinopathy
A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects
The purpose of this study is to determine the safety and efficacy of Vitreosolve in diabetic retinopathy patients.
- Trial name
- NCT00664183
- Testing
- Vitreosolve
- Where
- 17 sites in United States, India
- Volunteers
- 400 people
- Sponsor
- Vitreoretinal Technologies, Inc.
Nonproliferative Diabetic Retinopathy
The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
The purpose of this study is to evaluate the safety and efficacy of subcutaneously administered AKB-9778 15mg once daily or 15mg twice daily for 12 months in patients with moderate to severe non-proliferative diabetic retinopathy…
- Trial name
- TIME-2b (NCT03197870)
- Testing
- AKB-9778
- Where
- 53 sites in United States
- Volunteers
- 167 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Diabetic Macular Edema (DME)
High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy
Patients with diabetic macular edema (DME) sometimes must undergo vitrectomy surgery (PPV) for diabetic and non-diabetic related issues.
- Trial name
- NCT06662994
- Testing
- Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Retina Consultants of Orange County
Non Proliferative Diabetic Retinopathy
Study to Evaluate Efficacy and Safety of Entelon 50mg in Patients With Non-Proliferative Diabetic Retinopathy
This clinical trial is a multi-center, double-blind, randomized, placebo controlled , parallel design, superiority, phase 4 study to evaluate the efficacy and safety of Entelon 50mg in 396 patients with non-proliferative diabetic…
- Trial name
- NCT05358080
- Testing
- Entelon Tab. 50mg
- Where
- South Korea
- Volunteers
- 396 people
- Sponsor
- Hanlim Pharm. Co., Ltd.
Diabetic Retinopathy
Extension Study of the Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy
This multicenter, open-label extension study will evaluate the long-term tolerability and safety for patients completing study CSMS995 0802.
- Trial name
- NCT00248157
- Testing
- Octreotide acetate in microspheres
- Volunteers
- 105 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes Mellitus, Mild Nonproliferative Diabetic Retinopathy
Biomarkers of Diabetic Retinopathy Progression
The purpose of this study is to validate a predictive model of diabetic retinopathy progression in patients with diabetes mellitus type 2 patients to clinically significant macular edema (CSME) needing treatment either…
- Trial name
- C-Tracer (NCT01607190)
- Where
- 2 sites in India, Portugal
- Volunteers
- 200 people
- Sponsor
- Association for Innovation and Biomedical Research on Light and Image
Type-2 Diabetes, Diabetic Retinopathy
Phenotypes of Nonproliferative Diabetic Retinopathy in DM 2 Patients Identified by OCT, CFP, RLA and mfERG (DIAMARKER)
To characterise phenotypes of Non Proliferative Diabetic Retinopathy (NPDR) progression using multimodal testing/imaging procedures.
- Trial name
- NCT01440660
- Where
- Portugal
- Volunteers
- 20 people
- Sponsor
- Association for Innovation and Biomedical Research on Light and Image
Diabetic Retinopathy
HORNBILL: A Study to Test Different Doses of BI 764524 in Patients Who Have Had Laser Treatment for a Type of Diabetic Eye Disease Called Diabetic Retinopathy With Diabetic Macular Ischemia
This is a study in people with a type of diabetic eye disease called diabetic retinopathy with diabetic macular ischemia. People who have had laser treatment for their diabetic retinopathy can participate in the study.
- Trial name
- HORNBILL (NCT04424290)
- Testing
- BI 764524
- Where
- 19 sites in United States, United Kingdom
- Volunteers
- 45 people
- Sponsor
- Boehringer Ingelheim
Non-Proliferative Diabetic Retinopathy, Cataract
Nepafenac Once Daily for Macular Edema - Study 2
The purpose of this study is to demonstrate superiority of Nepafenac Ophthalmic Suspension, 0.3% dosed once daily relative to Nepafenac Vehicle based upon clinical outcomes among diabetic participants following cataract surgery.
- Trial name
- NCT01872611
- Testing
- Nepafenac Ophthalmic Suspension, 0.3%, Vehicle, Prednisolone acetate
- Volunteers
- 819 people
- Sponsor
- Alcon Research
Diabetic Retinopathy
Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy
The most common ocular disease in patients with diabetes, diabetic retinopathy, is present in approximately 40% of diabetic patients; about 8% of diabetic patients have vision threatening diabetic retinopathy.
- Trial name
- NCT00130845
- Testing
- Octreotide Acetate in Microspheres
- Where
- United States
- Volunteers
- 312 people
- Sponsor
- Novartis
Non-Proliferative Diabetic Retinopathy
Clinical Study on the Efficacy and Safety of TNTL in the Treatment of Non-proliferative Diabetic Retinopathy
The goal of this clinical trial is to learn if drug TNTL works to treat non-proliferative diabetic retinopathy in adults. It will also learn about the safety of drug TNTL. The main questions it aims to answer are: 1.
- Trial name
- TNTL (NCT06817265)
- Testing
- TNTL, TNTL simulation preparation
- Where
- 30 sites in China
- Volunteers
- 360 people
- Sponsor
- Beletalent (Zhuhai) Pharmaceutical Co., Ltd
Diabetic Macular Edema
Efficacy and Safety of Conbercept for Diabetic Macular Edema Combined With Severe Non-proliferative Diabetic Retinopathy
The goal of this prospective multicenter open label study is to evaluate the efficacy and safety of intravitreal injection Conbercept (IVC) for the treatment of diabetic macular edema (DME) combined with severe nonproliferative…
- Trial name
- NCT06305143
- Testing
- Conbercept
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Shanghai Eye Disease Prevention and Treatment Center
Non-Proliferative Diabetic Retinopathy
Safety and Efficacy of Faricimab in Patients With NPDR
The purpose of this Phase 2 study is comprised of two groups to evaluate the safety, tolerability, and efficacy of faricimab in patients with Non-Proliferative Diabetic Retinopathy.
- Trial name
- MAGIC (NCT05681884)
- Testing
- Faricimab
- Where
- 16 sites in United States
- Volunteers
- 179 people
- Sponsor
- Greater Houston Retina Research
Diabetic Macular Edema, Sleep Apnea
Diabetic Macular Edema - Obstructive Sleep Apnea Relationship Study
The purpose of this study is to evaluate the relationship between DME and obstructive sleep apnea (OSA). OSA impacts millions of North Americans, many of whom are undiagnosed.
- Conditions
- Diabetic Macular Edema, Sleep Apnea, Non Proliferative Diabetic Retinopathy
- Trial name
- DME-OSA (NCT03597815)
- Testing
- Aflibercept 40 MG/ML [Eylea], OSA diagnostic test - overnight sleep study, CPAP therapy for OSA positive patients
- Where
- Canada
- Volunteers
- 150 people
- Sponsor
- Uptown Eye Specialists
Non Proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy
Changes in Electroretinogram and Contrast Sensitivity After PASCAL Treatment
Laser photocoagulation has become the treatment of choice in PDR. Laser photocoagulation has become the treatment of choice in PDR.
- Trial name
- NCT00563043
- Testing
- PASCAL laser treatment
- Where
- Mexico
- Volunteers
- 8 people
- Sponsor
- Asociación para Evitar la Ceguera en México
Non-proliferative Diabetic Retinopathy, Diabetes Mellitus Type 2
Efficacy of Ubiquinone and Combined Antioxidant Therapy in Non-proliferative Diabetic Retinopathy
The purpose of this study is to evaluate the efficacy of ubiquinone and combined antioxidant therapy on progression, clinical regression, oxidative stress markers and mitochondrial dysfunction in non-proliferative diabetic…
- Trial name
- NCT02062034
- Testing
- Ubiquinone, Combined antioxidant therapy
- Where
- Mexico
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- University of Guadalajara
Diabetic Retinopathy, Sleep Apnea
CPAP Effect on the Progression of Diabetic Retinopathy in Patients With Sleep Apnea
Objectives: Main objective: To compare the percentage of patients with new microaneurysm or hard exudates after 12 months between the CPAP group and the control group.
- Trial name
- RetinAS (NCT02874313)
- Testing
- Continuous positive airway pressure, Pharmacological treatment, Conventional anti-diabetic diet recommendations
- Where
- Spain
- Volunteers
- 82 people
- Sponsor
- Hospital Universitario La Paz